Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163659354> ?p ?o ?g. }
- W3163659354 endingPage "996" @default.
- W3163659354 startingPage "986" @default.
- W3163659354 abstract "Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate composed of a novel enzyme-cleavable linker and membrane-permeable topoisomerase I inhibitor payload. T-DXd has been approved for HER2-positive metastatic breast cancer and for HER2-positive metastatic gastric cancer. The approval in breast cancer was based on results from the DESTINY-Breast01 (U201; NCT03248492) and J101 (NCT02564900) trials. Here, we present dose justification for the approved 5.4 mg/kg every-3-weeks (Q3W) dose based on exposure-efficacy evaluated in patients with HER2-positive breast cancer (N = 337) from these 2 trials. Exposure-safety was assessed in patients with all tumor types (N = 639, n = 512 with breast cancer) across 5 trials, including J101 and DESTINY-Breast01. T-DXd doses ranged from 0.8-8.0 mg/kg Q3W; most patients received 5.4 (n = 312) or 6.4 mg/kg (n = 291). For each end point, multivariate logistic or Cox regression analysis was performed using various exposure metrics of T-DXd and released drug. A statistically significant association was observed between intact T-DXd area under the concentration-time curve (AUC) and confirmed objective response rate (ORR; P = 0.028). No significant exposure-response relationships were observed between intact T-DXd or released drug and duration of response or progression-free survival; however, follow-up was limited. All evaluated safety end points demonstrated a significant (P < 0.05) relationship with either intact T-DXd or released drug, with higher adverse event (AE) rates projected at higher exposures. Dose-response projections suggested an increase in ORR (67.5% vs. 62.9%) and toxicity (e.g., grade ≥ 3 all-cause treatment-emergent AEs: 61% vs. 54%) with T-DXd 6.4 vs. 5.4 mg/kg. Results demonstrate the benefit-risk profile at different doses and guide clinicians in the use of the 5.4-mg/kg Q3W dose in patients with HER2-positive metastatic breast cancer." @default.
- W3163659354 created "2021-05-24" @default.
- W3163659354 creator A5007169910 @default.
- W3163659354 creator A5008356782 @default.
- W3163659354 creator A5008549101 @default.
- W3163659354 creator A5020674154 @default.
- W3163659354 creator A5021541475 @default.
- W3163659354 creator A5023859191 @default.
- W3163659354 creator A5032755579 @default.
- W3163659354 creator A5034353627 @default.
- W3163659354 creator A5052001379 @default.
- W3163659354 creator A5052010553 @default.
- W3163659354 creator A5069272944 @default.
- W3163659354 creator A5083945008 @default.
- W3163659354 creator A5087648612 @default.
- W3163659354 date "2021-06-10" @default.
- W3163659354 modified "2023-09-28" @default.
- W3163659354 title "Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan" @default.
- W3163659354 cites W1913616561 @default.
- W3163659354 cites W1987133729 @default.
- W3163659354 cites W2076263734 @default.
- W3163659354 cites W2081082908 @default.
- W3163659354 cites W2092714009 @default.
- W3163659354 cites W2139721771 @default.
- W3163659354 cites W2140259056 @default.
- W3163659354 cites W2314772071 @default.
- W3163659354 cites W2567068937 @default.
- W3163659354 cites W2578064406 @default.
- W3163659354 cites W2660853336 @default.
- W3163659354 cites W2760931533 @default.
- W3163659354 cites W2911680403 @default.
- W3163659354 cites W2917113139 @default.
- W3163659354 cites W2942867242 @default.
- W3163659354 cites W2943729639 @default.
- W3163659354 cites W2994378455 @default.
- W3163659354 cites W2996630100 @default.
- W3163659354 cites W3095813411 @default.
- W3163659354 doi "https://doi.org/10.1002/cpt.2291" @default.
- W3163659354 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8518417" @default.
- W3163659354 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33999422" @default.
- W3163659354 hasPublicationYear "2021" @default.
- W3163659354 type Work @default.
- W3163659354 sameAs 3163659354 @default.
- W3163659354 citedByCount "15" @default.
- W3163659354 countsByYear W31636593542022 @default.
- W3163659354 countsByYear W31636593542023 @default.
- W3163659354 crossrefType "journal-article" @default.
- W3163659354 hasAuthorship W3163659354A5007169910 @default.
- W3163659354 hasAuthorship W3163659354A5008356782 @default.
- W3163659354 hasAuthorship W3163659354A5008549101 @default.
- W3163659354 hasAuthorship W3163659354A5020674154 @default.
- W3163659354 hasAuthorship W3163659354A5021541475 @default.
- W3163659354 hasAuthorship W3163659354A5023859191 @default.
- W3163659354 hasAuthorship W3163659354A5032755579 @default.
- W3163659354 hasAuthorship W3163659354A5034353627 @default.
- W3163659354 hasAuthorship W3163659354A5052001379 @default.
- W3163659354 hasAuthorship W3163659354A5052010553 @default.
- W3163659354 hasAuthorship W3163659354A5069272944 @default.
- W3163659354 hasAuthorship W3163659354A5083945008 @default.
- W3163659354 hasAuthorship W3163659354A5087648612 @default.
- W3163659354 hasBestOaLocation W31636593542 @default.
- W3163659354 hasConcept C121608353 @default.
- W3163659354 hasConcept C126322002 @default.
- W3163659354 hasConcept C143998085 @default.
- W3163659354 hasConcept C197934379 @default.
- W3163659354 hasConcept C2775930923 @default.
- W3163659354 hasConcept C2779786085 @default.
- W3163659354 hasConcept C2780035454 @default.
- W3163659354 hasConcept C530470458 @default.
- W3163659354 hasConcept C71924100 @default.
- W3163659354 hasConcept C98274493 @default.
- W3163659354 hasConceptScore W3163659354C121608353 @default.
- W3163659354 hasConceptScore W3163659354C126322002 @default.
- W3163659354 hasConceptScore W3163659354C143998085 @default.
- W3163659354 hasConceptScore W3163659354C197934379 @default.
- W3163659354 hasConceptScore W3163659354C2775930923 @default.
- W3163659354 hasConceptScore W3163659354C2779786085 @default.
- W3163659354 hasConceptScore W3163659354C2780035454 @default.
- W3163659354 hasConceptScore W3163659354C530470458 @default.
- W3163659354 hasConceptScore W3163659354C71924100 @default.
- W3163659354 hasConceptScore W3163659354C98274493 @default.
- W3163659354 hasIssue "4" @default.
- W3163659354 hasLocation W31636593541 @default.
- W3163659354 hasLocation W31636593542 @default.
- W3163659354 hasLocation W31636593543 @default.
- W3163659354 hasOpenAccess W3163659354 @default.
- W3163659354 hasPrimaryLocation W31636593541 @default.
- W3163659354 hasRelatedWork W188069312 @default.
- W3163659354 hasRelatedWork W2001196910 @default.
- W3163659354 hasRelatedWork W2092771806 @default.
- W3163659354 hasRelatedWork W2130521606 @default.
- W3163659354 hasRelatedWork W2158916914 @default.
- W3163659354 hasRelatedWork W2401868633 @default.
- W3163659354 hasRelatedWork W2896532861 @default.
- W3163659354 hasRelatedWork W2931400096 @default.
- W3163659354 hasRelatedWork W2934076975 @default.
- W3163659354 hasRelatedWork W2342209702 @default.
- W3163659354 hasVolume "110" @default.